These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 11850163

  • 1. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
    Speciale A, Musumeci R, Blandino G, Milazzo I, Caccamo F, Nicoletti G.
    Int J Antimicrob Agents; 2002 Feb; 19(2):111-8. PubMed ID: 11850163
    [Abstract] [Full Text] [Related]

  • 2. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
    Behra-Miellet J, Dubreuil L, Jumas-Bilak E.
    Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
    [Abstract] [Full Text] [Related]

  • 3. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2001 Nov; 47(2):90-6. PubMed ID: 11173809
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates.
    Snydman DR, Jacobus NV, McDermott LA.
    Antimicrob Agents Chemother; 2011 Jan; 55(1):421-5. PubMed ID: 21041506
    [Abstract] [Full Text] [Related]

  • 5. Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.
    Wagner J, Jabbusch M, Eisenblätter M, Hahn H, Wendt C, Ignatius R.
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2358-61. PubMed ID: 12821499
    [Abstract] [Full Text] [Related]

  • 6. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
    Pong A, Thomson KS, Moland ES, Chartrand SA, Sanders CC.
    J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
    [Abstract] [Full Text] [Related]

  • 7. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
    Milazzo I, Blandino G, Musumeci R, Nicoletti G, Lo Bue AM, Speciale A.
    Int J Antimicrob Agents; 2002 Dec; 20(6):451-6. PubMed ID: 12458140
    [Abstract] [Full Text] [Related]

  • 8. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J, Bachoual R, Ouabdesselam S, Boudjadja A, Soussy CJ.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [Abstract] [Full Text] [Related]

  • 9. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
    Johnson AP, Warner M, Livermore DM.
    Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
    [Abstract] [Full Text] [Related]

  • 10. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
    Aktaş Z, Gönüllü N, Salcioğlu M, Bal C, Anğ O.
    Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
    Hoogkamp-Korstanje JA, Roelofs-Willemse J.
    J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
    [Abstract] [Full Text] [Related]

  • 12. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
    Presterl E, Mueller-Uri P, Grisold A, Georgopoulos A, Graninger W.
    Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
    [Abstract] [Full Text] [Related]

  • 13. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A, Petersen U, Endermann R.
    Chemotherapy; 1996 Jul; 42(6):410-25. PubMed ID: 8957575
    [Abstract] [Full Text] [Related]

  • 14. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
    Edlund C, Sabouri S, Nord CE.
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ.
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [Abstract] [Full Text] [Related]

  • 17. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
    Tarasi A, Capone A, Tarasi D, Cassone M, Bianco G, Venditti M.
    J Antimicrob Chemother; 1999 Jun; 43(6):833-5. PubMed ID: 10404324
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
    Edmiston CE, Krepel CJ, Kehl KS, Seabrook GR, Somberg LB, Almassi GH, Smith TL, Loehrl TA, Brown KR, Lewis BD, Towne JB.
    J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.